Araujo RLC, Herman P, Riechelmann RP. Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review. World J Clin Oncol 2017; 8(3): 266-272 [PMID: 28638797 DOI: 10.5306/wjco.v8.i3.266]
Corresponding Author of This Article
Raphael LC Araujo, MD, PhD, Department of Upper Gastrointestinal and Hepato-Pancreato-Bliliary Sugery, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, SP 14784-400, Brazil. raphael.araujo@hcancerbarretos.com.br
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Comparison of original planned and analyzed design of randomized clinical trials with patients who underwent surgery and additional chemotherapy for initially resectable colorectal liver metastases
Citation: Araujo RLC, Herman P, Riechelmann RP. Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review. World J Clin Oncol 2017; 8(3): 266-272